JP2023517162A - 枯草菌及びエンドヌクレアーゼを使用したヒト塩基性線維芽細胞増殖因子の生成 - Google Patents
枯草菌及びエンドヌクレアーゼを使用したヒト塩基性線維芽細胞増殖因子の生成 Download PDFInfo
- Publication number
- JP2023517162A JP2023517162A JP2022523843A JP2022523843A JP2023517162A JP 2023517162 A JP2023517162 A JP 2023517162A JP 2022523843 A JP2022523843 A JP 2022523843A JP 2022523843 A JP2022523843 A JP 2022523843A JP 2023517162 A JP2023517162 A JP 2023517162A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- intein
- bfgf
- acid construct
- bacillus subtilis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000014469 Bacillus subtilis Nutrition 0.000 title claims description 38
- 244000063299 Bacillus subtilis Species 0.000 title claims description 36
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 title claims description 13
- 108010042407 Endonucleases Proteins 0.000 title description 3
- 102000004533 Endonucleases Human genes 0.000 title description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 78
- 230000017730 intein-mediated protein splicing Effects 0.000 claims abstract description 72
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 62
- 229920001184 polypeptide Polymers 0.000 claims abstract description 61
- 238000000034 method Methods 0.000 claims abstract description 30
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 29
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 27
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 27
- 239000013604 expression vector Substances 0.000 claims abstract description 26
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 13
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 13
- 239000002157 polynucleotide Substances 0.000 claims abstract description 13
- 241000192542 Anabaena Species 0.000 claims abstract description 9
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 65
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 64
- 230000014509 gene expression Effects 0.000 claims description 39
- 238000010367 cloning Methods 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 239000013592 cell lysate Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 238000004587 chromatography analysis Methods 0.000 claims description 10
- 229920000936 Agarose Polymers 0.000 claims description 9
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 9
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 9
- 239000008101 lactose Substances 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 7
- 108010071146 DNA Polymerase III Proteins 0.000 claims description 6
- 102000007528 DNA Polymerase III Human genes 0.000 claims description 6
- 238000005277 cation exchange chromatography Methods 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 238000011144 upstream manufacturing Methods 0.000 claims description 6
- 238000003780 insertion Methods 0.000 claims description 5
- 230000037431 insertion Effects 0.000 claims description 5
- 238000013518 transcription Methods 0.000 claims description 4
- 230000035897 transcription Effects 0.000 claims description 4
- 239000003623 enhancer Substances 0.000 claims description 3
- 241000192531 Anabaena sp. Species 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims description 2
- 108010013829 alpha subunit DNA polymerase III Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 61
- 102000004169 proteins and genes Human genes 0.000 abstract description 50
- 210000004027 cell Anatomy 0.000 description 46
- 239000013598 vector Substances 0.000 description 17
- 239000012634 fragment Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 239000002609 medium Substances 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 12
- 229930027917 kanamycin Natural products 0.000 description 8
- 229960000318 kanamycin Drugs 0.000 description 8
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 8
- 229930182823 kanamycin A Natural products 0.000 description 8
- 239000013605 shuttle vector Substances 0.000 description 8
- 230000006698 induction Effects 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000012807 shake-flask culturing Methods 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000001742 protein purification Methods 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical group C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- -1 etc.) Proteins 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000016434 protein splicing Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011978 dissolution method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 101150109249 lacI gene Proteins 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009465 prokaryotic expression Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 101100273253 Rhizopus niveus RNAP gene Proteins 0.000 description 1
- 102400000827 Saposin-D Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 108010053098 biotin receptor Proteins 0.000 description 1
- 229930189065 blasticidin Natural products 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000012444 downstream purification process Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000011013 endotoxin removal Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000012527 feed solution Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000008394 flocculating agent Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 108091008147 housekeeping proteins Proteins 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 101150009573 phoA gene Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011027 product recovery Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07007—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/101—Plasmid DNA for bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
インテインは、宿主タンパク質から自動的に切除されて、ペプチド結合によるフランキング配列の連結を触媒可能なタンパク質因子である。
本文中で使用する「外来ポリペプチド」、「外来タンパク質」、「異種ポリペプチド」及び「異種タンパク質」との用語は互換的に使用可能である。これらは、宿主細胞に自然発現するのではなく、人為的に加えるか、遺伝子導入等の技術により宿主細胞に発現させるポリペプチド又はタンパク質である。
本文中で使用する「アフィニティタグ」、「精製タグ」及び「タンパク質タグ」との用語は互換的に使用可能である。これらは、組換えタンパク質の生成プロセスで目的タンパク質と融合して発現するタンパク質又はポリペプチドである。アフィニティタグは、目的タンパク質の可溶性及び安定性を促進するために使用可能であり、目的タンパク質の検出及び精製を容易とする。
一実施方案において、本発明は、発現ベクターを提供する。当該発現ベクターは本発明の核酸構造体を含む。
いくつかの実施方案において、本発明は、形質転換された宿主細胞を提供する。当該宿主細胞は本発明の発現ベクターを含む。枯草菌はエンドトキシンを含まないため、「一般に安全と認められる」と認定されている。そこで、本発明の一実施形態では、宿主細胞として枯草菌を採用する。本発明の発明者は、驚くべきことに、本発明の核酸構造体の構造を採用することで、枯草菌はインテインとエクステインの自動切除を促進可能となり、満足のいく天然型の外来ポリペプチド/タンパク質の発現レベルを得られることを見出した。これにより、枯草菌における外来ポリペプチド/タンパク質の発現レベルが低いとの課題が解決される。
いくつかの実施方案において、本発明は、外来ポリペプチドの産生方法を提供する。当該方法は、前記外来ポリペプチドの発現が可能な条件で、本発明の形質転換された枯草菌を培養することを含む。
大腸菌/枯草菌発現シャトルベクターの作製及び設計
pRB374及びpBR322をそれぞれ大腸菌/枯草菌発現シャトルベクターの開始ベクターとして用いた。具体的には、以下の修飾ステップによってpECBS1を作製した。まず、SalI及びBglIIでpRB374(5.9kb)を消化した。同じSalI及びBglIIを用いて2つの部位を消化したあと、ショットガンポリメラーゼ連鎖反応で産生したT7 RNAポリメラーゼ-Lacプロモーター-LacI遺伝子-LacIqプロモーター-ブレオマイシン耐性遺伝子-ネオマイシン耐性遺伝子の部分断片(5.3 kb)で置換して、pECBSiベクターを形成した。続いて、形成したpECBSiベクター及びpBR322ベクターをそれぞれEcoRI及びBglIで消化し、pECBSiの消化断片をpBR322(4.3kb)の消化により取得した断片で置換して、pECBS1シャトルベクターを形成した。
大腸菌/枯草菌発現シャトルベクター(pECBS1-H6-DnaE-bFGF)の作製方法は、次の通りとした。サーモフィッシャーサイエンティフィック社によって、SEQ ID NO:5で示すEcoRI-T7プロモーター(T7)-ラクトースオペロン(LacO)-リボソーム結合部位(RBS)-6x-Hisタグ(H6)-Asp-DnaE int-c(DnaE)-bFGF-T7転写ターミネーター-XbaI配列をコードするDNA断片を合成した。次に、合成した前記DNA断片をEcoRI及びXbaIで消化したあと、同様の2種類の制限酵素で枯草菌/大腸菌シャトルベクターpECBS1の連結を消化した。そして、最終的に、pECBS1-H6-DnaE-bFGF構造体を取得した(図1参照)。取得した構造体についての酵素切断の鑑定結果を図7に示す。
WB800の単一コロニーを5mlの培地A(1x Spizizen塩溶液、0.5%グルコース、0.005%トリプトファン、0.02%カザミノ酸、0.5%酵母抽出物、0.8%アルギニン、0.4%ヒスチジンを含有)に移植し、37℃、200rpmで一晩培養した。その後、一晩経過した培養物0.5mlを50mlの培地Aに継代し、37℃、200rpmでA600=1.7となるまで培養した。次に、1mlの87%グリセリンを10mlの培養物に加え、氷上に15分載置した。そして、1mlの培養物を更に20mlの培地B(1x Spizizen塩、0.5%グルコース、0.0005%トリプトファン、0.01%カザミノ酸、0.1%酵母抽出物、2.5mM MgCl2、0.5mM CaCl2を含む)に継代し、30℃、150rpmで2時間培養した。続いて、1mlの培養物をマイクロ遠心チューブに移し、終濃度1mMでEGTAを加えて室温で5分間培養した。その後、2ugのプラスミドDNAを1mlのコンピテント状態のWB800に加え、37℃、200rpmで引き続き2時間成長させた。そして、室温、5000rpmで遠心分離し、形質転換されたWB800を収集するとともに、100ulの培養物上清液に再懸濁した。また、形質転換されたWB800をカナマイシン耐性プレートにプレーティングし、37℃で一晩培養した。
振とうフラスコ培養
25μg/mlのカナマイシンが添加された200mlの2x LB培地において、枯草菌の形質転換体を37℃(250rpm)で成長させた。そして、A600値が1.0に達した時点で、終濃度0.2mMのIPTGを添加した。その後、3時間間隔で1mlの培地サンプルを収集し、bFGFの発現分析に用いた。細胞沈殿を200μlの再懸濁バッファー(50mM Tris-Cl、200mM EDTA、pH8.0)に再懸濁してから、氷上で5分間培養した。次に、37℃で120μlのリゾチーム溶液(10mg/mL)を用い、混合物を20分間処理した。その後、80μlの溶解バッファー(10mM EDTA、10% Triton X-100及び50mM Tris-Cl、pH8.0)を加えた。続いて、溶液が充填された試験管を静かに倒立させて、14800rpmで5分間遠心分離を行った。そして、ウエスタンブロットによって、細胞破砕物サンプルにおけるbFGFタンパク質の発現状況を分析した。
25μg/mlのカナマイシンが添加された200mlの2x LB培地において、枯草菌の形質転換体を37℃(回転速度250rpm)でA600=1.0となるまで成長させた。次に、50mlの培養物を2Lフラスコ(25μg/mlのカナマイシンが添加された450mlの2x LB培地を含む)に移し、温度37℃(250rpmで回転)を条件として、A600値が1.0に達するまで引き続き培養した。続いて、25μg/mlのカナマイシンが添加された3.5Lの2x LB培地を充填した5Lの発酵槽に培養物全体を移植し、1MのNaOHを添加して培養物のpHを7.0に維持した。培養物のpO2値(酸素分圧)は1.5vvmとした。また、pHが上昇し始めた場合には、50%のグルコース供給溶液を添加して、培養物のpHを7.0に維持した。そして、A600=8になったあと、終濃度0.2mMのIPTGを加えて誘導培養を行った。また、1MのH2SO4を用いてpH調節を維持した。そして、2時間間隔で培養物サンプルを収集し、bFGF発現の分析に用いた。
陽イオン交換クロマトグラフィー及びヘパリン-アガロースクロマトグラフィーをbFGFの精製に用いた。まず、Nanodrop Microvolume分光光度計を使用して、溶出画分のタンパク質濃度を測定した。また、有意な数値(約1mg/ml)を有する溶出画分をまとめて、0.1x PBで透析を行った。その後、クマシーブリリアントブルーR-250で染色した10% SDS-PAGEゲル電気泳動によって、精製bFGFのバンドを取得した。そして、SDS-PAGEゲルからbFGFタンパク質を含むバンドを回収し、後続のLC-MSによる分析に使用した。
MTT法(MTT比色法とも称する)によって、NIH/3T3線維芽細胞の増殖に対する精製bFGFタンパク質の影響を測定した。具体的なステップは次の通りとした。NIH/3T3細胞(密度を2×104細胞とする)を96ウェルマイクロプレートに移植し、37℃、5%CO2、1%ウシ胎児血清添加DMEM培地で24時間飢餓培養したあと、異なる濃度のbFGFを使用して細胞を3日間処理した。次に、終濃度0.5mg/mLの3-(4,5-ジメチルチアゾール-2-イル)-2,5-ジフェニルテトラゾリウムブロミド(MTT)をマイクロプレートの各穴に加え、37℃、5%CO2で4h培養した。その後、全ての溶液をプレートから除去し、150μlのDMSOを加えて紫色の結晶を溶解した。続いて、プレートを暗闇で10分間継続的に振とうし、570nmで酵素結合免疫測定装置により吸光度を読み取った。
Claims (13)
- インサートを含み、前記インサートは、5’末端から3’末端にかけて、短ペプチドアフィニティタグ、アナベナ(Anabaena sp.)由来のトランススプライシングインテイン、及び外来ポリペプチドをコードするポリヌクレオチド配列を含み、前記短ペプチドアフィニティタグは、前記トランススプライシングインテインのN-エクステインとなり、前記外来ポリペプチドは前記トランススプライシングインテインのC-エクステインとなる核酸構造体。
- 前記インテインは、アナベナDNAポリメラーゼIIIユニットのインテイン(Asp DnaE)である請求項1に記載の核酸構造体。
- 前記インテインは、SEQ ID NO:2と少なくとも75%の配列同一性を有するアミノ酸配列を含む請求項1又は2に記載の核酸構造体。
- 前記インテインは、SEQ ID NO:2で示される配列からなる請求項1又は2に記載の核酸構造体。
- 前記外来ポリペプチドは線維芽細胞増殖因子(FGF)であり、例えば、塩基性線維芽細胞増殖因子(bFGF)であり、特に、ヒトbFGFである請求項1~4のいずれか1項に記載の核酸構造体。
- 前記短ペプチドアフィニティタグは、約4~15個のアミノ酸の長さを有しており、例えば、5~15xHisタグであり、特に、6xHisタグである請求項1~5のいずれか1項に記載の核酸構造体。
- 更に、プロモーター、オペロン、エンハンサー及びリボソーム結合部位のうちの1種類又は複数種類の因子を含む請求項1~6のいずれか1項に記載の核酸構造体。
- 5’末端から3’末端にかけて、T7プロモーター-ラクトースオペロン-リボソーム結合部位(RBS)-6xHisタグ-Asp DnaEインテイン-bFGF-T7転写ターミネーターをコードするヌクレオチド配列を含む請求項1~7のいずれか1項に記載の核酸構造体。
- 更に、前記インサートの上流に位置する第1クローニングサイトと、前記インサートの下流に位置する第2クローニングサイトを含み、前記第1クローニングサイトと第2クローニングサイトは、発現ベクターへの前記核酸構造体の挿入を可能とする請求項1~8のいずれか1項に記載の核酸構造体。
- 請求項1~9のいずれか1項に記載の核酸構造体を含む発現ベクター。
- 請求項10に記載の発現ベクターを含む形質転換された枯草菌(Bacillus subtilis)。
- 前記外来ポリペプチドの発現が可能な条件で、請求項11に記載の形質転換された枯草菌を培養することを含む外来ポリペプチドの産生方法。
- 更に、培養した前記枯草菌を分離し、破砕して細胞破砕液を取得したあと、陽イオン交換クロマトグラフィー及びヘパリン-アガロース(HA)クロマトグラフィーを順に使用することで、前記細胞破砕液から前記外来ポリペプチドを精製することを含む請求項12に記載の外来ポリペプチドの産生方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010164821.4 | 2020-03-11 | ||
CN202010164821.4A CN111235174A (zh) | 2020-03-11 | 2020-03-11 | 利用枯草芽孢杆菌和核酸内切酶制备人碱性成纤维细胞生长因子 |
PCT/CN2021/075070 WO2021179860A1 (zh) | 2020-03-11 | 2021-02-03 | 利用枯草芽孢杆菌和核酸内切酶制备人碱性成纤维细胞生长因子 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023517162A true JP2023517162A (ja) | 2023-04-24 |
Family
ID=70875343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022523843A Pending JP2023517162A (ja) | 2020-03-11 | 2021-02-03 | 枯草菌及びエンドヌクレアーゼを使用したヒト塩基性線維芽細胞増殖因子の生成 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230151374A1 (ja) |
JP (1) | JP2023517162A (ja) |
KR (1) | KR20220152186A (ja) |
CN (2) | CN111235174A (ja) |
WO (1) | WO2021179860A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111235174A (zh) * | 2020-03-11 | 2020-06-05 | 梦芊科技知识产权有限公司 | 利用枯草芽孢杆菌和核酸内切酶制备人碱性成纤维细胞生长因子 |
CN114073759A (zh) * | 2020-08-18 | 2022-02-22 | 梦芊科技知识产权有限公司 | 一种皮肤伤口愈合制剂 |
CN114246936A (zh) * | 2020-09-25 | 2022-03-29 | 梦芊科技知识产权有限公司 | 用于促进毛发生长或毛囊再生或预防或治疗毛发脱落的组合物、方法和用途 |
CN114762732A (zh) * | 2021-01-13 | 2022-07-19 | 梦芊科技知识产权有限公司 | 控释微球及其抗衰老的用途 |
CN113755421B (zh) * | 2021-09-28 | 2024-04-12 | 梦芊细胞因子有限公司 | 一种用于covid-19的口服性疫苗及抗体加强剂 |
CN114990089B (zh) * | 2022-05-26 | 2023-01-17 | 广州市乾相生物科技有限公司 | 微型内含肽Ssa DnaH及其在表达分离六肽-8中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012100176A2 (en) * | 2011-01-20 | 2012-07-26 | University Of Rochester | Macrocyclic compounds with a hybrid peptidic/non-peptidic backbone and methods for their preparation |
JP2019195327A (ja) * | 2018-05-07 | 2019-11-14 | チュ チイ ラム, | 枯草菌(bacillus subtilis)において真正で生物活性を有する塩基性線維芽細胞増殖因子を発現させる方法及び手段 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7271256B2 (en) * | 2000-02-04 | 2007-09-18 | New England Biolabs, Inc. | Method for producing circular or multimeric protein species in vivo or in vitro and related methods |
WO2008076938A1 (en) * | 2006-12-14 | 2008-06-26 | University Of Iowa Research Foundation | Method of making cyclic polypeptides with inteins |
CN102676534B (zh) * | 2012-04-12 | 2014-07-16 | 上海育臣生物工程技术有限公司 | 一种利用内含肽制备胸腺素多肽的方法 |
HUE062276T2 (hu) * | 2016-01-29 | 2023-10-28 | Univ Princeton | Kivételes splicing aktivitású osztott inteinek |
CN111235174A (zh) * | 2020-03-11 | 2020-06-05 | 梦芊科技知识产权有限公司 | 利用枯草芽孢杆菌和核酸内切酶制备人碱性成纤维细胞生长因子 |
-
2020
- 2020-03-11 CN CN202010164821.4A patent/CN111235174A/zh active Pending
- 2020-05-14 CN CN202010408981.9A patent/CN113388633B/zh active Active
-
2021
- 2021-02-03 WO PCT/CN2021/075070 patent/WO2021179860A1/zh active Application Filing
- 2021-02-03 KR KR1020227012275A patent/KR20220152186A/ko unknown
- 2021-02-03 JP JP2022523843A patent/JP2023517162A/ja active Pending
-
2022
- 2022-08-23 US US17/821,658 patent/US20230151374A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012100176A2 (en) * | 2011-01-20 | 2012-07-26 | University Of Rochester | Macrocyclic compounds with a hybrid peptidic/non-peptidic backbone and methods for their preparation |
JP2019195327A (ja) * | 2018-05-07 | 2019-11-14 | チュ チイ ラム, | 枯草菌(bacillus subtilis)において真正で生物活性を有する塩基性線維芽細胞増殖因子を発現させる方法及び手段 |
Also Published As
Publication number | Publication date |
---|---|
KR20220152186A (ko) | 2022-11-15 |
WO2021179860A1 (zh) | 2021-09-16 |
CN113388633A (zh) | 2021-09-14 |
CN111235174A (zh) | 2020-06-05 |
CN113388633B (zh) | 2023-11-10 |
US20230151374A1 (en) | 2023-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2023517162A (ja) | 枯草菌及びエンドヌクレアーゼを使用したヒト塩基性線維芽細胞増殖因子の生成 | |
EP0946711B1 (en) | Improved expression vectors | |
US11702456B2 (en) | Systems and methods for the production of diphtheria toxin polypeptides | |
WO2007022623A1 (en) | Regulation of heterologous recombinant protein expression in methylotrophic and methanotrophic bacteria | |
CA3098910A1 (en) | A method for optimizing antibody expression | |
JP2019195327A (ja) | 枯草菌(bacillus subtilis)において真正で生物活性を有する塩基性線維芽細胞増殖因子を発現させる方法及び手段 | |
CA2770557C (en) | Vector comprising mannose promoter and mannose promoter | |
US20120196323A1 (en) | Fermentation Process | |
CN114073759A (zh) | 一种皮肤伤口愈合制剂 | |
RU2700452C1 (ru) | Рекомбинантная плазмидная днк ptrx-tevrs-ртн, кодирующая гибридный белок, способный к протеолитическому расщеплению с образованием фрагмента эндогенного человеческого паратиреоидного гормона (1-34), штамм escherichia coli bl21(de3)/ptrx-tevrs-ртн - продуцент указанного белка и способ получения рекомбинантного pth (1-34) | |
CN114075571A (zh) | 表皮生长因子的核酸构建体、生产方法及其组合物 | |
JP2004524845A5 (ja) | ||
JP2004524845A (ja) | ポリペプチドの製造方法 | |
JP2688174B2 (ja) | ストレプトミセスStreptomycesからの生物活性ヒト顆粒球マクロフアージコロニー刺激因子(GM−CSF)及びその他の異種蛋白質の分泌に関する発現系 | |
RU2821947C2 (ru) | Способ получения мембранного белка | |
JP2023139191A (ja) | Crm197タンパク質発現方法 | |
RU2496877C2 (ru) | ПЛАЗМИДНЫЙ ВЕКТОР pHYP С ПОВЫШЕННОЙ СЕГРЕГАЦИОННОЙ СТАБИЛЬНОСТЬЮ ДЛЯ ЭКСПРЕССИИ РЕКОМБИНАНТНОГО БЕЛКА, БАКТЕРИЯ - ПРОДУЦЕНТ ПРЕДШЕСТВЕННИКА РЕКОМБИНАНТНОГО БЕЛКА И СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО БЕЛКА | |
WO2024133316A1 (en) | Closed system for expressing recombinant proteins using e. coli and methods for producing clarified cell cultures thereof | |
JP2005046068A (ja) | 蛋白質生産用の新規なバクテリア及び蛋白質の製造方法 | |
JPS61280292A (ja) | 菌体外分泌による蛋白質の製造法 | |
CN111278852A (zh) | 重组欧氏杆菌天冬酰胺酶的生产方法 | |
JPS633800A (ja) | 菌体外分泌による蛋白質の製造法 | |
KR20100096567A (ko) | 신규한 그람 양성균 박테리아 발현 시스템 | |
JP2000078989A (ja) | ヒト成長ホルモンの分泌生産方法 | |
JP2524693C (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220824 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230815 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231114 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240214 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240423 |